Inclusion Criteria:

          -  Ability of participant or Legally Authorized Representative (LAR) to understand this
             study, and participant or LAR willingness to sign a written informed consent.

          -  Have confirmed diagnosis of squamous cell cancer or cutaneous squamous cell cancer or
             basal cell carcinoma.

          -  Have one or more tumors measuring at least 5 mm in diameter.

          -  No prior therapy for this malignancy.

          -  Women of child-bearing potential and men with partners of child-bearing potential must
             agree to practice sexual abstinence, or to use two forms of adequate contraception
             (hormonal AND barrier method of birth control) prior to study entry, for the duration
             of study participation until the end of study treatment. If a woman becomes pregnant
             or suspects she is pregnant while participating in this study, she should inform her
             treating physician immediately.

          -  Men of child-bearing potential must not father a child or donate sperm while on this
             study until the end of study treatment.

          -  Physician feels the patient is medically fit for the trial.

        Exclusion Criteria:

          -  Current or anticipated use of other investigational agents while participating in this
             study.

          -  Pregnant or breast feeding. There is a potential for congenital abnormalities and for
             this regimen to harm breast feeding infants (if applicable) Planned treatment with
             chemotherapy and/or radiation therapy prior to standard of care surgery. Concurrent
             treatment with anti-cancer therapy is not allowed.

          -  Hypersensitivity to Copaxone® or glatiramer acetate, mannitol, or any component of the
             formulation.

          -  A known condition that leads to immunosuppression such as Acquired Immunodeficiency
             Syndrome (AIDS) or concurrent use of immunosuppressive therapy.